Relay Therapeutics prices IPO at $400M
The company, whose drug-discovery efforts are focused on protein motion and detection of interactions that occur anywhere on a protein rather than only at active sites, filed to go public last month.
Protein motion-focused Relay Therapeutics files for $200M IPO
The company, which combines computational technology with biology and chemistry to uncover new drug targets, has a drug in clinical development and plans to start clinical studies of another one later this year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Beam Therapeutics raises $180M in IPO
The company was founded to develop base editing, a form of gene editing that alters genes at the single-letter level rather than using the "cutting" technique typical of CRISPR/Cas9. Beam had filed to go public in September, aiming at raising $100 million.
Gene editing company Beam Therapeutics aims for $100M IPO
The company, officially launched in 2018 after operating in stealth mode for a year, is developing technologies to enable genome editing at the single-letter level, as opposed to the "cutting" of DNA and RNA normally used in CRISPR/Cas9.
NYSE changes fee schedule in bid to woo biotech companies
Starting on Saturday, the exchange is instituting a discount on its annual listing fee for pre-revenue companies, capping it at $100,000 per year over three years. While the policy applies across industries, it is an effort to draw biotech companies that would usually list on the Nasdaq.
Four biotech companies announce pricings of IPOs, looking to raise more than $300M
NextCure, Milestone Pharmaceuticals, Cortexyme and Axcella Health all said Wednesday that they would begin trading on the Nasdaq Thursday.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Gossamer Bio becomes 2019’s second biotech ‘unicorn’ to go public
The company, which had previously sought to use a legal but potentially risky workaround, expects to raise $276 million.
Alector, developing immunity-based neurological disease drugs, goes public
The "immuno-neurology" company expects to raise $176 million in the offering, which it expects to close on Monday.
Gossamer Bio goes public despite government shutdown halting most SEC operations
It was reported earlier this week in The Wall Street Journal that, while an IPO without the SEC signing off is allowed with a certain workaround, it is carries legal and regulatory risks.
Report sees strong year ahead for life sciences IPOs despite headwinds
The report, by law firm WSGR, noted an almost twofold increase in life sciences IPOs - especially biotech - and a greater number priced at $250 million or more.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Harpoon Therapeutics files for $86.25M IPO
The company's Form S-1 filing comes less than two months after it completed a $70 million Series C financing.
These are the biggest biopharma stories we covered in 2018
A roundup of some of the biggest trends and events in pharmaceuticals, biotechnology and diagnostics in 2018, including regulatory approvals, international trends, national policy and more.
Moderna raises more than $600M in biggest-ever biotech IPO
The offering closes on Tuesday and follows a string of very large IPOs by biotech companies over the last couple of months. Moderna's February $500 million Series G round valued the company at $7 billion.
Report: Diagnostics unicorn Grail considering an IPO in the US, possibly next year
Bloomberg had reported in February that the biotechnology startup company was considering a $500 million fund raise for a listing in Hong Kong, but reconsidered due to market conditions.
Centrexion Therapeutics changes its mind on initial public offering
The Boston-based company said it would not pursue a planned IPO, citing "market conditions." Nasdaq had agreed to its listing on Tuesday.